Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk
- PMID: 24664291
- PMCID: PMC4016103
- DOI: 10.1161/HYPERTENSIONAHA.114.03231
Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk
Abstract
Aging and abnormal aldosterone regulation are both associated with vascular disease. We hypothesized that aldosterone dysregulation influences the age-related risk of renal vascular and cardiovascular disease. We conducted an analysis of 562 subjects who underwent detailed investigations under conditions of liberal and restricted dietary sodium intake (1124 visits) in the General Clinical Research Center. Aldosterone regulation was characterized by the ratio of maximal suppression to stimulation (supine serum aldosterone on a liberal sodium diet divided by the same measure on a restricted sodium diet). We previously demonstrated that higher levels of this Sodium-modulated Aldosterone Suppression-Stimulation Index (SASSI) indicate greater aldosterone dysregulation. Renal plasma flow (RPF) was determined via p-aminohippurate clearance to assess basal renal hemodynamics and the renal vascular responses to dietary sodium manipulation and angiotensin II infusion. Cardiovascular risk was calculated using the Framingham Risk Score. In univariate linear regression, older age (β=-4.60; P<0.0001) and higher SASSI (β=-58.63; P=0.001) predicted lower RPF and a blunted RPF response to sodium loading and angiotensin II infusion. We observed a continuous, independent, multivariate-adjusted interaction between age and SASSI, where the inverse relationship between SASSI and RPF was most apparent with older age (P<0.05). Higher SASSI and lower RPF independently predicted higher Framingham Risk Score (P<0.0001) and together displayed an additive effect. Aldosterone regulation and age may interact to mediate renal vascular disease. Our findings suggest that the combination of aldosterone dysregulation and renal vascular dysfunction could additively increase the risk of future cardiovascular outcomes; therefore, aldosterone dysregulation may represent a modifiable mechanism of age-related vascular disease.
Keywords: aging; aldosterone; renal plasma flow; renin-angiotensin system.
Conflict of interest statement
Figures
References
-
- Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J. 2007;54:359–370. - PubMed
-
- Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab. 2005;16:104–107. - PubMed
-
- Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis. 1999;33:261–266. - PubMed
-
- Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: Cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008;19:88–90. - PubMed
-
- Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638–2645. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- L30 HL104553/HL/NHLBI NIH HHS/United States
- M01-RR02635/RR/NCRR NIH HHS/United States
- UD7HP25059/PHS HHS/United States
- UL1RR025758/RR/NCRR NIH HHS/United States
- P50 HL055000/HL/NHLBI NIH HHS/United States
- K24 HL103845/HL/NHLBI NIH HHS/United States
- T32 HL007609/HL/NHLBI NIH HHS/United States
- U54 LM008748/LM/NLM NIH HHS/United States
- U54LM008748/LM/NLM NIH HHS/United States
- UL1 RR025758/RR/NCRR NIH HHS/United States
- K23 HL11177/HL/NHLBI NIH HHS/United States
- M01 RR002635/RR/NCRR NIH HHS/United States
- P50HL055000/HL/NHLBI NIH HHS/United States
- K23 HL111771/HL/NHLBI NIH HHS/United States
- R01 HL114765/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
